Clinical trials: Pemetrexed
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Cancer
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
The purpose of this study is to compare the effects (good and bad) of chemoradiotherapy with or without Bevacizumab (Avastin). Chemoradiotherapy is the combination of chemotherapy (the drugs pemetrexed and cetuximab) and…
- Trial name
- NCT00703976
- Testing
- Bevacizumab, Cetuximab, Pemetrexed
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pittsburgh
Carcinoma, Small Cell
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer.
- Trial name
- NCT00129974
- Testing
- pemetrexed and gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Non-small Cell Lung Cancer
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)
In this single-arm, phase II clinical trial, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC received neoadjuvant therapy with furmonertinib (oral, 80 mg once daily, stopped 1 week preoperatively) in combination with…
- Trial name
- NCT05430802
- Testing
- Furmonertinib+cisplating/pemetrexed
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Squamous Cell Carcinoma of Head and Neck
Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck
The aim of the study is to evaluate the efficacy and safety of pemetrexed monotherapy as salvage treatment in patients with relapsed or metastatic squamous cell carcinoma of head and neck.
- Trial name
- NCT01333696
- Testing
- Pemetrexed
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Carcinoma, Non-Small-Cell Lung
A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI
It has not been established whether platinum-based doublets is better than single agent chemotherapy in EGFR mutant NSCLC patients who failed first-line EGFR TKI.
- Trial name
- NCT03050437
- Testing
- Cisplatin, Pemetrexed
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Samsung Medical Center
Malignant Pleural Mesothelioma
Trimodality Therapy for Malignant Pleural Mesothelioma
The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is still controversial. The selection criterion to perform either Extrapleural Pneumonectomy (EPP) or Pleurectomy/Decortication (P/D) is…
- Trial name
- NCT01343264
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- HSK Wiesbaden
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of programmed cell death 1 (PD-1) inhibitors in advanced lung cancer, such as pembrolizumab…
- Trial name
- NCT04856176
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
- Trial name
- NCT04162015
- Testing
- Nivolumab, Pemetrexed, Cisplatin or Carboplatin
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Small Cell
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed…
- Trial name
- NCT00191750
- Testing
- Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Solid Cancers
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or…
- Trial name
- NCT01301716
- Testing
- GDC-0980, bevacizumab, carboplatin
- Where
- 5 sites in United States, Spain
- Volunteers
- 75 people
- Sponsor
- Genentech, Inc.
Local Advanced Non-Small Cell Lung Cancer
Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the recommended dose of pemetrexed and the maximum tolerated dose of radiotherapy when using concurrent pemetrexed/cisplatin/radiotherapy in the patients with local advanced non-small…
- Trial name
- NCT00846443
- Testing
- Concurrent Pemetrexed, Cisplatin and Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Lung Adenocarcinoma
Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1002. The study is a prospective, single-center, open-label, single-armed, phase II clinical trial.
- Trial name
- NCT02980991
- Testing
- Pemetrexed, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Urologic Neoplasms
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
- Trial name
- NCT00034593
- Testing
- ALIMTA, gemcitabine
- Where
- 9 sites in Finland, France and 1 more
- Sponsor
- Eli Lilly and Company
Leptomeningeal Metastases
Intrathecal Pemetrexed for Leptomeningeal Metastasis
Intrathecal chemotherapy is one of the most important treatment modalities for leptomeningeal metastasis of solid tumors. In the previous study(Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastasis From Non-small Cell…
- Trial name
- NCT05289908
- Testing
- Pemetrexed (1), Pemetrexed (2), Folic Acid
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Hospital of Jilin University
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Trial name
- NCT03366766
- Testing
- Nivolumab, Cisplatin, Pemetrexed Disodium
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-small Cell Lung Cancer
Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Non small cell lung cancer is the first cause of cancer related death in France and is becoming an increasing health problem in developing countries.
- Trial name
- CALMETTE (NCT02507518)
- Testing
- PET scan imaging
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Centre Henri Becquerel
Ovarian Cancer, Peritoneal Cancer
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00230542
- Testing
- Carboplatin, Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Primary Peritoneal Cancer
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
The purpose of this study is to determine efficacy of the combination therapy of pemetrexed and carboplatin as treatment for patients with platinum-sensitive ovarian cancer.
- Trial name
- NCT00489359
- Testing
- Pemetrexed - Phase 1, Carboplatin - Phase 1, Pemetrexed - Phase 2
- Where
- 22 sites in Argentina, Canada and 3 more
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company